Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!
news

“Ultrasensitive” HPV detection paves way for precision treatment

Posted: 28 September 2021 | | No comments yet

A new study sequenced tumour DNA for the “ultrasensitive” detection of HPV, further honing precision treatment of the illness.

Human Papillomavirus (HPV)

A team at the Princess Margaret Cancer Centre, Canada, have discovered a novel sequencing method that provides “ultrasensitive” detection of the human papillomavirus (HPV) in a person’s blood. According to the researchers, these findings could lead to better precision treatments of the disease.

Previous science in the field has proven that HPV, which causes cancers in the throat, mouth and genital areas, can be found in the bloodstream but tests have had limited sensitivity. 

Dr Scott Bratman explained that one of the ways to more accurately detect HPV in the blood is to use liquid biopsy approaches or blood-based biomarkers, one of which is circulating tumour DNA, in order to monitor how the treatment is progressing. In this study, the sequencing method detected 20-fold lower levels of HPV circulating tumour DNA in a cohort of patients with advanced cervix cancer, making it a promising new method to monitor the disease and personalise therapies.

 

Access your FREE copy

 


Biomarkers aren’t just supporting drug discovery – they’re driving it

FREE market report

From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.

What you’ll unlock:

  • How biomarkers are guiding dose selection and early efficacy decisions in complex trials
  • Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
  • What makes lab data regulatory-ready and why alignment matters from day one

Explore how biomarkers are shaping early drug development

Access the full report – it’s free!

 

“We are really at the cusp of a revolution from a technology, clinical implementation and standard of care standpoint, where five to 10 years from now we will not be treating everybody with the same dose of radiation and chemotherapy and then waiting months to see if the treatment was effective,” Bratman stated. “I am confident we will be giving much more tailored doses.”

This technique could also be used to detect and guide treatment for viruses other than HPV that cause cancer such as certain types of stomach cancer and lymphomas. The work conducted by the team will also make it possible for further study in the field, refining the approach using larger study groups and eventually, practice-changing clinical trials.

Co-first author Dr Kathy Han added the research team first started enrolling patients with cervical cancer to this study in 2015. “The promising results from this wonderful collaboration with Dr Bratman will enable us to personalise patients’ treatment in the future,” she concluded.

The study was published in Clinical Cancer Research.